Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease.

Su C, Lichtenstein GR, Krok K, Brensinger CM, Lewis JD.

Gastroenterology. 2004 May;126(5):1257-69. Review.

PMID:
15131785
2.

A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis.

Su C, Lewis JD, Goldberg B, Brensinger C, Lichtenstein GR.

Gastroenterology. 2007 Feb;132(2):516-26. Epub 2006 Dec 20. Review.

PMID:
17258720
3.

Meta-analysis: factors predicting post-operative recurrence with placebo therapy in patients with Crohn's disease.

Pascua M, Su C, Lewis JD, Brensinger C, Lichtenstein GR.

Aliment Pharmacol Ther. 2008 Sep 1;28(5):545-56. doi: 10.1111/j.1365-2036.2008.03774.x. Epub 2008 Jun 28.

4.

Meta-analysis: remission and response from control arms of randomized trials of biological therapies for active luminal Crohn's disease.

Tinè F, Rossi F, Sferrazza A, Orlando A, Mocciaro F, Scimeca D, Olivo M, Cottone M.

Aliment Pharmacol Ther. 2008 Jun;27(12):1210-23. doi: 10.1111/j.1365-2036.2008.03681.x. Epub 2008 Mar 14. Review.

5.

Meta-analysis of the placebo rates of clinical relapse and severe endoscopic recurrence in postoperative Crohn's disease.

Renna S, Cammà C, Modesto I, Cabibbo G, Scimeca D, Civitavecchia G, Mocciaro F, Orlando A, Enea M, Cottone M.

Gastroenterology. 2008 Nov;135(5):1500-9. doi: 10.1053/j.gastro.2008.07.066. Epub 2008 Aug 3. Review.

PMID:
18823987
6.

Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis.

Khan KJ, Ullman TA, Ford AC, Abreu MT, Abadir A, Marshall JK, Talley NJ, Moayyedi P.

Am J Gastroenterol. 2011 Apr;106(4):661-73. doi: 10.1038/ajg.2011.72. Epub 2011 Mar 15. Review. Erratum in: Am J Gastroenterol. 2011 May;106(5):1014. Abadir, A [corrected to Abadir, Amir].

PMID:
21407187
7.

Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.

Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, Spehlmann ME, Rutgeerts PJ, Tulassay Z, Volfova M, Wolf DC, Hernandez C, Bornstein J, Sandborn WJ; International Efficacy of Natalizumab in Crohn's Disease Response and Remission (ENCORE) Trial Group.

Gastroenterology. 2007 May;132(5):1672-83. Epub 2007 Mar 21.

PMID:
17484865
8.

Efficacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis.

Ford AC, Kane SV, Khan KJ, Achkar JP, Talley NJ, Marshall JK, Moayyedi P.

Am J Gastroenterol. 2011 Apr;106(4):617-29. doi: 10.1038/ajg.2011.71. Epub 2011 Mar 15. Review.

PMID:
21407190
9.

Defining the optimal response criteria for the Crohn's disease activity index for induction studies in patients with mildly to moderately active Crohn's disease.

Thia KT, Sandborn WJ, Lewis JD, Loftus EV Jr, Feagan BG, Steinhart AH, Hanauer SB, Persson T, Sands BE.

Am J Gastroenterol. 2008 Dec;103(12):3123-31. doi: 10.1111/j.1572-0241.2008.02176.x.

PMID:
18786111
10.

Oral Pentasa in the treatment of active Crohn's disease: A meta-analysis of double-blind, placebo-controlled trials.

Hanauer SB, Strömberg U.

Clin Gastroenterol Hepatol. 2004 May;2(5):379-88.

PMID:
15118975
11.

Long-term antibiotic treatment for Crohn's disease: systematic review and meta-analysis of placebo-controlled trials.

Feller M, Huwiler K, Schoepfer A, Shang A, Furrer H, Egger M.

Clin Infect Dis. 2010 Feb 15;50(4):473-80. doi: 10.1086/649923. Review.

PMID:
20067425
12.

A meta-analysis of antimycobacterial therapy for Crohn's disease.

Borgaonkar MR, MacIntosh DG, Fardy JM.

Am J Gastroenterol. 2000 Mar;95(3):725-9.

PMID:
10710065
13.

Comparison of two dosing methods for induction of response and remission with oral budesonide in active pediatric Crohn's disease: a randomized placebo-controlled trial.

Levine A, Kori M, Dinari G, Broide E, Shaoul R, Yerushalmi B, On A, Bujanover Y, Pröls M, Greinwald R; Israeli Pediatric Budesonide Study Group.

Inflamm Bowel Dis. 2009 Jul;15(7):1055-61. doi: 10.1002/ibd.20881.

PMID:
19229988
14.

Meta-analysis of the placebo response in ulcerative colitis.

Garud S, Brown A, Cheifetz A, Levitan EB, Kelly CP.

Dig Dis Sci. 2008 Apr;53(4):875-91. Epub 2007 Oct 13.

PMID:
17934839
15.

A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease.

Reinisch W, Panés J, Lémann M, Schreiber S, Feagan B, Schmidt S, Sturniolo GC, Mikhailova T, Alexeeva O, Sanna L, Haas T, Korom S, Mayer H.

Am J Gastroenterol. 2008 Sep;103(9):2284-92. doi: 10.1111/j.1572-0241.2008.02024.x. Epub 2008 Jul 30.

PMID:
18671816
16.

Systematic review: the potential influence of mesalazine formulation on maintenance of remission in Crohn's disease.

Steinhart AH, Forbes A, Mills EC, Rodgers-Gray BS, Travis SP.

Aliment Pharmacol Ther. 2007 Jun 15;25(12):1389-99. Review.

17.

Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables.

Cammà C, Giunta M, Rosselli M, Cottone M.

Gastroenterology. 1997 Nov;113(5):1465-73.

PMID:
9352848
18.

How effective are current drugs for Crohn's disease? A meta-analysis.

Salomon P, Kornbluth A, Aisenberg J, Janowitz HD.

J Clin Gastroenterol. 1992 Apr;14(3):211-5.

PMID:
1532974
19.

Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial.

Schreiber S, Feagan B, D'Haens G, Colombel JF, Geboes K, Yurcov M, Isakov V, Golovenko O, Bernstein CN, Ludwig D, Winter T, Meier U, Yong C, Steffgen J; BIRB 796 Study Group.

Clin Gastroenterol Hepatol. 2006 Mar;4(3):325-34.

PMID:
16527696
20.

Supplemental Content

Support Center